Clinical trials: Progression
Biomarker, Progression
Soluble B7-H3 as a Biomarker for Osteosarcoma
Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies.
- Conditions
- Biomarker, Progression, Osteosarcoma, Surveillance
- Trial name
- NCT05942456
- Testing
- ELISA: enzyme-linked immunosorbent assay
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Primary Brain Tumor
Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry
The NeuroBlate® System (NBS), is a minimally invasive robotic laser thermotherapy tool. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions.
- Trial name
- NCT02389855
- Testing
- NeuroBlate® System Therapy
- Where
- 9 sites in United States
- Volunteers
- 144 people
- Sponsor
- Monteris Medical
Myopia Progression, Axial Length, Eye
Low Dose Atropine Eye Drops in Myopic Egyptian Children
Previous Studies reported that low concentration atropine eye drops may be effective in increasing the choroidal blood flow and thickness and this slows myopia progression.
- Conditions
- Myopia Progression, Axial Length, Eye, Sclera Thickness
- Trial name
- LAMP (NCT06265454)
- Testing
- low dose atropine eye drops
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Ain Shams University
HIV
HIV Infection and Risk Related Coinfections/Comorbidities in Indonesia
INA-PROACTIVE is a multicenter, prospective, observational cohort study of HIV positive antiretroviral-naïve and treatment-experienced individuals. No investigational treatment or intervention will be used by this study.
- Trial name
- INAPROACTIVE (NCT03663920)
- Where
- 19 sites in Indonesia
- Volunteers
- 4,336 people
- Sponsor
- Ina-Respond
CD19 Positive, CD22 Positive
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia…
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease
- Trial name
- NCT04029038
- Testing
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Parkinson Disease
Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials
An observational study to characterize and compare long-term clinical outcomes data collected remotely through periodic tele-visits, interactive smartphone app sessions, and web-based surveys in individuals with Parkinson's…
- Trial name
- AT-HOME PD (NCT03538262)
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Massachusetts General Hospital
COVID-19 Respiratory Infection
Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI
Clinical research includes Determination of efficacy and acceptability of the local medicine "Rutan tablets 0,025" in children and teenagers 6-18 years old with COVID-19 and/or acute respiratory viral infections.
- Trial name
- NCT05862883
- Testing
- Rutan 25 mg, Control group
- Where
- Uzbekistan
- Volunteers
- 301 people
- Sponsor
- Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan
Survival Without Progression
A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.
To establish the anti-tumour effect of this metronomic combination regimen defined by progression-free survival (PFS) after two cycles of treatment (4 months) and 12 months of treatment, as well as response rate after any number…
- Trial name
- SFCE METRO 01 (NCT01285817)
- Testing
- celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,
- Where
- France
- Volunteers
- 79 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
HIV Disease Progression
Acceptability, Feasibility and Effectiveness of Online Peer Support Group for ART Adherence Among Youth
In Uganda, Youth living with HIV/AIDS (YLHIVA) enrolled in HIV treatment experience suboptimal treatment adherence and have lower viral load suppression (VLS) rates compared to younger children or adults.
- Trial name
- NCT05688709
- Testing
- WhatsApp peer support group
- Where
- 3 sites in Uganda
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- Infectious Diseases Research Collaboration, Uganda
Viral Pneumonia, COVID
Imaging Feature of SARS-CoV2 Infection
The novel coronavirus SARS-CoV2 clinically presents with pneumonia, characterised by fever, cough, dyspnea. The severity of the disease varies widely with evidence of mild disease in the majority of confirmed cases, severe…
- Trial name
- COVID19IF (NCT04394026)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Francesco De Cobelli
Myopia Progression
Effect of Orthokeratology on Myopia Progression in French Children
To evaluate and to compare the effect of orthokeratology (OK) on axial elongation in French myopic children.
- Trial name
- NCT05700240
- Testing
- orthokeratology, single-vision spectacle correction
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Anaplastic Ependymoma, Ependymoma
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
Background: Ependymomas are rare tumors that arise from the ependyma. That is a tissue of the central nervous system. They can develop in the brain or the spine.
- Conditions
- Anaplastic Ependymoma, Ependymoma, Ependymomas
- Trial name
- NCT03727841
- Testing
- Marizomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Myopic Progression
Monthly Replacement Orthokeratology for Myopia Control in Young Children
The two-year prospective study aims at investigating frequently replacement effect on myopia control in young children, and the use of weekly protein removal system in monthly replacement modality orthokeratology lenses on…
- Trial name
- MR2 (NCT04293328)
- Testing
- orthokeratology, Menicon Progent A+B
- Where
- Hong Kong
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Myopic Progression
Monthly Replacement Orthokeratology for Myopia Control in Existing Lens Wearers
The two-year prospective study aims at investigating the benefits of frequent replacement (monthly) orthokeratology lenses in myopia control in terms of effectiveness in control and prevention of ocular complications.
- Trial name
- MR1 (NCT04295707)
- Testing
- orthokeratology, Menicon Progent A+B
- Where
- Hong Kong
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
HIV/AIDS, COVID-19
COVID-19 in Patients With HIV
Currently, limited data is available about patients with HIV in the context of the COVID-19 pandemic. People with HIV who have not achieved viral suppression through antiretroviral treatment may have a compromised immune system…
- Conditions
- HIV/AIDS, COVID-19, SARS-CoV-2
- Trial name
- NCT04333953
- Testing
- No intervention
- Where
- United States
- Volunteers
- 412 people
- Sponsor
- University of Missouri-Columbia
Myopic Progression
Effects of Different Designs of Orthokeratology Lens on Myopia Control and Visual Quality
This study was aimed to evaluate the effects of different Orthokeratology，including the size of central optical zone and the height of peripheral reverse curve, on myopia control and visual quality.
- Trial name
- NCT05192824
- Testing
- Orthokeratology lens
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tianjin Eye Hospital
Multiple Myeloma
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and…
- Trial name
- NCT01109004
- Testing
- Lenalidomide, lenalidomide, bortezomib and dexamethasone
- Where
- 54 sites in United States
- Volunteers
- 758 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HIV Infections
A Study of HIV-Disease Development in Aging
The purpose of this study is to better understand the relationship between age and HIV disease progression. This study will explore the possible relationship between age and HIV disease progression.
- Trial name
- NCT00006144
- Testing
- Lopinavir/Ritonavir, Emtricitabine, Stavudine
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
To compare nelfinavir (NFV) with ritonavir (RTV) for delaying disease progression or death in HIV-infected patients with CD4+ cell counts less than 100 cells/mm3 [AS PER AMENDMENT 3/11/98: less than or equal to 200 cells/mm3].
- Trial name
- NCT00000859
- Testing
- Indinavir sulfate, Ritonavir, Nelfinavir mesylate
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Progression of Rheumatoid Arthritis, Osteoarthritis of Multiple Joints
To Examine Whether or Not the Primary Causes of OA or RA Might be Bone Alterations
Generally, osteoarthris (OA) is considered as primarily cartilage disease. However, as we and others have previously reported, a portion of OA might be caused primarily by bone alterations.
- Trial name
- NCT02327650
- Testing
- The examinations for bones in joints of OA and RA patients
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shinshu University